難治性2型糖尿病に対する臨床試験 (CAPTAIN-T2D) (CAPTAIN-T2D)
クロフトリベンとプラセボによる難治性2型糖尿病に対する第2相試験 (CAPTAIN-T2D)
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
調査の概要
詳細な説明
CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.
The trial consists of two parts.
Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.
During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Chandler、Arizona、アメリカ、85225
- 募集
- Arizona Clinical Trials - Pecos
-
コンタクト:
- Kamila Manager
- 電話番号:480-470-4000
- メール:kojeda@azclinicaltrials.com
-
Tucson、Arizona、アメリカ、85711
- 募集
- Arizona Clinical Trials - Broadway
-
コンタクト:
- Leanne Manager
- 電話番号:480-470-4000
- メール:lbuchenholz@azclinicaltrials.com
-
-
California
-
Fountain Valley、California、アメリカ、92708
- 募集
- Ark Clinical Research - Fountain Valley
-
コンタクト:
- Lizeth Manager
- 電話番号:323-588-1990
- メール:lsuncin@velocityclinical.com
-
Huntington Park、California、アメリカ、90255
- 募集
- Velocity Clinical Research, Huntington Park
-
コンタクト:
- Tim Manager
- 電話番号:5135799911
- メール:tpeterson@velocityclinical.com
-
La Mesa、California、アメリカ、91942
- 募集
- Velocity Clinical Research - Gardena
-
コンタクト:
- Tim Manager
- 電話番号:513-673-4057
- メール:tpeterson@velocityclinical.com
-
Long Beach、California、アメリカ、90815
- 募集
- Ark Clinical Research - Long Beach
-
コンタクト:
- Mike Manager
- 電話番号:562-997-1000
- メール:mdelgado@arkclinicalresearch.com
-
Los Angeles、California、アメリカ、90057
- 募集
- Velocity Clinical Research, Los Angeles
-
コンタクト:
- Tim Manager
- 電話番号:5135799911
- メール:tpeterson@velocityclinical.com
-
Los Angeles、California、アメリカ、90015
- 募集
- Los Angeles Institute for Metabolic Research
-
コンタクト:
- Lourdes Manager
- 電話番号:(213) 373-8380
- メール:lgaribay@metabolic.la
-
Northridge、California、アメリカ、98433
- 募集
- Amicis Research Center- Nordhoff
-
コンタクト:
- Veronica Clinical Research Manager
- 電話番号:(818) 929-7774
- メール:veronica.macias@amicisresearch.com
-
San Diego、California、アメリカ、92120
- 募集
- Alliance Clinical San Diego
-
コンタクト:
- Sandra Manager
- 電話番号:(858) 299-0009
- メール:SMisic@allianceclinicalnetwork.com
-
-
Florida
-
Edgewater、Florida、アメリカ、32132
- 募集
- Velocity Clinical Research, New Smyrna Beach
-
コンタクト:
- Tim Manager
- 電話番号:513-673-4057
- メール:tpeterson@velocityclinical.com
-
Fort Lauderdale、Florida、アメリカ、33312
- 募集
- The Center for Diabetes and Endocrine Care
-
コンタクト:
- Marie Study Coordinator
- 電話番号:ext 236 954-963-7191
- メール:mmartin@diabetes-endocare.com
-
Miami、Florida、アメリカ、33173
- 募集
- Admed Research LLC
-
コンタクト:
- Indiana Manager
- 電話番号:786-687-2882
- メール:igonzalez@admedresearch.com
-
New Port Richey、Florida、アメリカ、34652
- 募集
- Suncoast Clinical Research, Inc
-
コンタクト:
- Cathy Manager
- 電話番号:727-849-4131
- メール:cbarnes@suncoastclinicalresearch.com
-
Port Charlotte、Florida、アメリカ、33952
- 募集
- Innovative Research Institute
-
コンタクト:
- Lauren Manager
- 電話番号:(+1) 2832276233
- メール:l.ellis@medpace.com
-
Port Orange、Florida、アメリカ、32127
- 募集
- Progressive Medical Research
-
コンタクト:
- Nora Clinical Research Manager
- 電話番号:3457 386-304-7070
- メール:norab@progressivemedicalresearch.com
-
Winter Park、Florida、アメリカ、32789
- 募集
- Conquest Research
-
コンタクト:
- Malisa Manager
- 電話番号:407-916-0060
- メール:malisa.agard@conquestresearch.com
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30303
- 募集
- Emory University School of Medicine
-
コンタクト:
- Rohit Manager
- 電話番号:404-778-1695
- メール:rohit.parab@emory.edu
-
Columbus、Georgia、アメリカ、31904
- 募集
- IACT Health-Brookstone Centre Pkwy
-
コンタクト:
- kristina Manager
- 電話番号:706.321.0495
- メール:kristina.erb@centricityresearch.com
-
-
Idaho
-
Boise、Idaho、アメリカ、83709
- 募集
- Paradigm Clinical Research - Boise, ID
-
コンタクト:
- Janaie Manager
- 電話番号:208-801-7440
- メール:jbounsana@paradigm-research.com
-
-
Illinois
-
Chicago、Illinois、アメリカ、60607
- 募集
- Chicago Clinical Research Institute
-
コンタクト:
- Manognya Clinical Research Manager
- 電話番号:303 3127913241
- メール:manognya@ccrii.us
-
-
Iowa
-
West Des Moines、Iowa、アメリカ、50226
- 募集
- Iowa Diabetes and Endocrinology Research Center
-
コンタクト:
- Crystal Manager
- 電話番号:515-207-7486
- メール:choffman@iderc.com
-
-
Kansas
-
Wichita、Kansas、アメリカ、67226
- 募集
- Alliance for Multispecialty Research - Wichita East
-
コンタクト:
- Terry Manager
- 電話番号:316-689-6635
- メール:terry.klein@amr-clinical.com
-
-
Kentucky
-
Edgewood、Kentucky、アメリカ、41017
- 募集
- St. Elizabeth Healthcare
-
コンタクト:
- Amber Manager
- 電話番号:859-655-1567
- メール:amber.avery@stelizabeth.com
-
-
Louisiana
-
Lafayette、Louisiana、アメリカ、70508
- 募集
- Velocity Clinical Research, Lafayette
-
コンタクト:
- Tim Manager
- 電話番号:513-673-4057
- メール:tpeterson@velocityclinical.com
-
Metairie、Louisiana、アメリカ、70006
- 募集
- NOLA Care Clinical Research
-
コンタクト:
- Rosina Manager
- 電話番号:504-427-6324
- メール:rosinaducote@gmail.com
-
New Orleans、Louisiana、アメリカ、70112
- 募集
- Tulane University School of Medicine
-
コンタクト:
- Neha Manager
- 電話番号:5049889803
- メール:nupadhyay@tulane.edu
-
-
Maryland
-
Rockville、Maryland、アメリカ、20854
- 募集
- Velocity Clinical Research, Rockville
-
コンタクト:
- Tim Manager
- 電話番号:513-673-4057
- メール:tpeterson@velocityclinical.com
-
-
Massachusetts
-
Springfield、Massachusetts、アメリカ、011030
- 募集
- Elixia SISU BHR - Springfield
-
コンタクト:
- Darlene Manager
- 電話番号:5617970336
- メール:darlene.djaba@empathxresearch.com
-
-
Michigan
-
Troy、Michigan、アメリカ、48085
- 募集
- Oakland Medical Research Center
-
コンタクト:
- Juliejo (Julie) Clinical Research Manager
- 電話番号:248-687-7412
- メール:juliejolafave@msn.com
-
-
Nebraska
-
Lincoln、Nebraska、アメリカ、68510
- 募集
- Velocity Clinical Research, Lincoln
-
コンタクト:
- Tim Manager
- 電話番号:513-673-4057
- メール:tpeterson@velocityclinical.com
-
Omaha、Nebraska、アメリカ、68134
- 募集
- Velocity Clinical Research, Omaha
-
コンタクト:
- Tim Manager
- 電話番号:513-673-4057
- メール:tpeterson@velocityclinical.com
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89148
- 募集
- Palm Research Center, Inc.
-
コンタクト:
- Raffaela Manager
- 電話番号:702-736-5161
- メール:raffaela@palmresearchcenter.com
-
Las Vegas、Nevada、アメリカ、89108
- 募集
- Alliance Clinical - Las Vegas
-
コンタクト:
- Stephanie Manager
- 電話番号:(702) 680-1500
- メール:sruvalcaba@allianceclinicalnetwork.com
-
-
New York
-
Albany、New York、アメリカ、12203
- 募集
- Albany Medical College
-
コンタクト:
- Mohammed Manager
- 電話番号:518-264-4462
- メール:ismailmoh@amc.edu
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27514
- 募集
- University of North Carolina at Chapel Hill
-
コンタクト:
- Jessica Manager
- 電話番号:984-974-3004
- メール:jessica_caffey@med.unc.edu
-
Greenville、North Carolina、アメリカ、27834
- 募集
- Physicians East
-
コンタクト:
- Kristen Manager
- 電話番号:252-413-6392
- メール:ktaylor@physicianseast.com
-
Morehead City、North Carolina、アメリカ、28557
- 募集
- Lucas Research Inc
-
コンタクト:
- Christina Manager
- 電話番号:252-222-5700
- メール:christina.tornes@centricityresearch.com
-
Wilmington、North Carolina、アメリカ、28401
- 募集
- PMG Research of Wilmington, LLC
-
コンタクト:
- Kevin Manager
- 電話番号:910.815.6108
- メール:cannon1099@me.com
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- 募集
- Velocity Clinical Research, Cincinnati, Mt. Auburn
-
コンタクト:
- Tim Manager
- 電話番号:513-673-4057
- メール:tpeterson@velocityclinical.com
-
Cincinnati、Ohio、アメリカ、45242
- 募集
- Velocity Clinical Research - Cincinnati, Blue Ash
-
コンタクト:
- Tim Manager
- 電話番号:513-673-4057
- メール:tpeterson@velocityclinical.com
-
Columbus、Ohio、アメリカ、43201
- 募集
- Endocrinology Associates, Inc
-
コンタクト:
- Edward Clinical Research Manager
- 電話番号:614-453-9999
- メール:ek@endocrinology-associates.com
-
Columbus、Ohio、アメリカ、43215
- 募集
- Remington Davis, Inc
-
コンタクト:
- Tsunami Clinical Research Manager
- 電話番号:614-487-2560
- メール:Tbrisco@remdavis.com
-
-
Oregon
-
Eugene、Oregon、アメリカ、97404
- 募集
- Willamette Valley Clinical Studies
-
コンタクト:
- Patricia Manager
- 電話番号:541-461-0132
- メール:drpatb@aol.com
-
-
Pennsylvania
-
West Chester、Pennsylvania、アメリカ、19380
- 募集
- Suburban Research Associates
-
コンタクト:
- Tom Manager
- 電話番号:610-891-9024
- メール:tfrancis@suburbanresearch.com
-
-
South Carolina
-
Anderson、South Carolina、アメリカ、29621
- 募集
- Velocity Clinical Research, Anderson
-
コンタクト:
- Tim Manager
- 電話番号:(864) 965-0190
- メール:tpeterson@velocityclinical.com
-
Mt. Pleasant、South Carolina、アメリカ、29464
- 募集
- Accellacare Charleston
-
コンタクト:
- Dhruva Manager
- 電話番号:(843) 849-1880
- メール:dhruva.patel@accellacare.com
-
-
Texas
-
Austin、Texas、アメリカ、78759
- 募集
- Velocity Clinical Research, Austin
-
コンタクト:
- Tim Manager
- 電話番号:513-673-4057
- メール:tpeterson@velocityclinical.com
-
Dallas、Texas、アメリカ、75230
- 募集
- Velocity Clinical Research - Dallas
-
コンタクト:
- Tim Manager
- 電話番号:(972) 566-8631
- メール:tpeterson@velocityclinical.com
-
Houston、Texas、アメリカ、77040
- 募集
- Juno Research, LLC
-
コンタクト:
- Lian manager
- 電話番号:713-779-5494
- メール:lian_ramos@junoresearch.us
-
Lampasas、Texas、アメリカ、76550
- 募集
- Radiance Clinical Research
-
コンタクト:
- Lauren Clinical Research Manager
- 電話番号:512-556-4130
- メール:lgarner@radianceclinical.com
-
Lewisville、Texas、アメリカ、75057
- 募集
- Alliance Clinical - Lewisville (Epic Clinical Research)
-
コンタクト:
- Jessica Manager
- 電話番号:(469) 361-8007
- メール:jpowell@allianceclinicalnetwork.com
-
Mission、Texas、アメリカ、78572
- 募集
- Texas Valley Clinical Research - Mission, TX
-
コンタクト:
- Omar Manager
- 電話番号:9568887400
- メール:gonzalez.md@tvcrmission.com
-
Round Rock、Texas、アメリカ、78681
- 募集
- Texas Diabetes & Endocrinology, P.A. - Round Rock
-
コンタクト:
- Olivia Clinical Research Manager
- 電話番号:512-334-3505
- メール:knutty@tderesearch.com
-
San Antonio、Texas、アメリカ、78229
- 募集
- Diabetes & Glandular Disease Clinic, P.A.
-
コンタクト:
- Myriam Manager
- 電話番号:1532 210-614-8612
- メール:myriam.turner@dgdclinic.com
-
San Antonio、Texas、アメリカ、78251
- 募集
- Texas Valley Clinical Research - San Antonio TX
-
コンタクト:
- Diana Manager
- 電話番号:2105431990
- メール:diana@tvcrtrials.com
-
Seabrook、Texas、アメリカ、77586
- 募集
- Elevate Clinical Research
-
コンタクト:
- Olga Clinical Research Manager
- 電話番号:832-271-1598
- メール:olga.konshina@elevateclinical.com
-
Weslaco、Texas、アメリカ、78596
- 募集
- Texas Valley Clinical Research, LLC
-
コンタクト:
- Czarina Manager
- 電話番号:956-431-8090
- メール:czarina@tvcrtrials.com
-
-
Utah
-
West Jordan、Utah、アメリカ、84088
- 募集
- Velocity Clinical Research, Salt Lake City
-
コンタクト:
- Tim Clinical Research Manager
- 電話番号:5135799911
- メール:tpeterson@velocityclinical.com
-
-
Virginia
-
Suffolk、Virginia、アメリカ、23435
- 募集
- Velocity Clinical Research, Suffolk
-
コンタクト:
- Tim Manager
- 電話番号:(757) 996-4200
- メール:tpeterson@velocityclinical.com
-
Vienna、Virginia、アメリカ、22182
- 募集
- Conquest Research
-
コンタクト:
- Henry Manager
- 電話番号:703-372-3268
- メール:Henry.Tran@conquestresearch.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
From Screening 1
-
Age at least 18 years.
-
HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).
-
Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).
-
Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.
-
Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.
-
At least one of the following
- ≥3 stable and adequate ADMs;
- diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
- hypertension requiring ≥2 adequately dosed AHMs;
- adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
- adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
- evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
- or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.
-
At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.
At Screening 2
- HbA1c ≥7.5% at Screening 2. At Day 1
- No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.
Exclusion Criteria:
-
New-onset diabetes (onset <1 year in the past).
-
Unwillingness to maintain with current glucose-lowering regimen during the trial.
-
Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.
-
Unwillingness to comply with CGM or other trial procedures.
-
Investigator considers the patient will otherwise be unwilling or unable to complete the trial.
-
Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.
-
Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).
-
Any of the following in medical history:
- Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
- A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
- Hypersensitivity or severe reaction to dexamethasone;
- Pheochromocytoma, or suspicion thereof;
- Anorexia, or other eating disorder;
- Glucocorticoid resistance;
- Multiple sclerosis;
- Significant hepatic impairment (e.g., Child-Pugh Class B or C);
- Idiopathic thrombocytopenic purpura;
- Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
- Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
- Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
- Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
- Any of the following in medication history:
- Any of the excluded medications listed in Section 6.9;
- Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
- Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
- Pregnancy (including a positive urine test) or current breast feeding.
From Screening 2
• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:
- wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
- a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
- supraclavicular/dorsocervical fat accumulation;
- irounding of the face (especially compared with prior photos);
- skin changes (violaceous striae, skin thinning, or excessive bruising);
- proximal muscle weakness on exam; or
- history of deep vein thrombosis/pulmonary embolism.
- Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
- Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
- Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
- Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
- Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
- Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
- Known hypersensitivity to clofutriben or to any of the product
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dose 1
clofutriben .2 mg oral tablet daily |
HSD-1 inhibitor
他の名前:
|
|
実験的:Dose 2
clofutriben 2mg oral tablet daily |
HSD-1 inhibitor
他の名前:
|
|
実験的:Dose 3
clofutriben 6mg oral tablet daily |
HSD-1 inhibitor
他の名前:
|
|
実験的:Dose 4
clofutriben 12 mg oral tablet daily |
HSD-1 inhibitor
他の名前:
|
|
プラセボコンパレーター:placebo
placebo control oral tablet daily |
Placebo |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
時間枠:8-10 hours after the dexamethasone 1 mg dose.
|
To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose. |
8-10 hours after the dexamethasone 1 mg dose.
|
|
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
時間枠:24 weeks.
|
To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
時間枠:24 weeks
|
To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To evaluate the safety of clofutriben in participants with T2D and EC.
時間枠:From enrollment until end of trial 9 month
|
Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose |
From enrollment until end of trial 9 month
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。